ClinicalTrials.gg
Enrolling by invitationNCT07177612LILAC-UNIUpdated Sep 22, 2025

Implementation Research on the LILAC Method to Educate Management of Elevated Lipoprotein(a).

An observational study in Lipoprotein(a) and Lipoprotein(a), Hyper-Lp(a)-Emia, sponsored by Changi General Hospital. Enrolling by invitation at 3 sites in 3 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Changi General Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20,000
Ages
16 Years and older
Sex
All
01

Study summary

The goal of this observational study is to assess the if short educational videos about #LILAC-for-Lpa are feasible and accepted in improving the confidence, testing, and management on Lipoprotein(a).

Read the detailed description

The aims of this study are to (1) assess the feasibility of using these educational videos about LILAC-for-Lp(a) to help improve confidence, testing and the management of Lp(a), (2) assess the acceptability in using short education videos about LILAC-for-Lp(a) and (3) to understand the knowledge gaps of Lp(a) in medical professionals through the additional questionnaire provided.

02

Conditions studied

  • Lipoprotein(a)
  • Lipoprotein(a), Hyper-Lp(a)-Emia

Keywords

  • LILAC-for-Lpa
  • Educational Videos
  • lipoprotein(a)
  • Lp(a)
03

In context

Lead sponsor

Changi General Hospital is the lead sponsor of 101 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Study populations include healthcare professionals, patients, and members of the public.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants include students, participants from institute of higher learning aged 16 and above.
  • Participants aged 16 and above regardless of local or overseas, may also be from educational talks that Dr Loh is invited to speak at.
  • Patients and members of the public aged 16 and above if they attend lipid awareness educational events.
  • Participants aged 16 and above in patient support groups or patient advocacy networks.

Exclusion criteria

Exclusion Criteria:

  • Participants aged below 16 years old.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Healthcare Professionals

    This group includes participants who are doctors, nurses, pharmacists, allied health and healthcare related students

  • Patients/Family/Public

    This group includes participants who have high Lipoprotein(a) levels, or their family members, or members of the public.

06

What researchers measure

Primary outcomes

  1. Improvement of Knowledge and awareness of Lp(a)

    Survey and questionnaire on participants to assess knowledge and awareness

    Time frame: From enrolment to 3 months after

Secondary outcomes

  1. Acceptance of Educational Videos

    Survey to determine if the educational videos are useful for them

    Time frame: From point of enrolment to 3 months

  2. Lipoprotein(a) Testing

    Survey to doctors on whether they are testing for Lipoprotein(a) in their patients prior to watching the educational videos, 3 months after, and 1 year after.

    Time frame: During enrolment to 1 year

07

Study locations

3 sites
08

References and documents

Publications

  • Loh WJ, Pang J, Simon O, Chan DC, Watts GF. Deficient perceptions and practices concerning elevated lipoprotein(a) among specialists in Singapore. Front Cardiovasc Med. 2025 Feb 14;12:1527351. doi: 10.3389/fcvm.2025.1527351. eCollection 2025. PubMed 40027516 ↗
  • Loh WJ, Watts GF, Lum E. A short educational video for improving awareness and confidence of healthcare professionals in managing lipoprotein(a): a pilot study based on LILAC-for-Lp(a). Eur J Cardiovasc Nurs. 2025 Jul 21;24(5):796-799. doi: 10.1093/eurjcn/zvaf052. No abstract available. PubMed 40156158 ↗

Individual participant data

Plan to share: No — This is an educational research survey

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07177612
Responsible party
Loh Wann Jia (Primary Investigator (Senior consultant endocrinologist), Changi General Hospital) — Principal investigator
First posted
Sep 17, 2025
Start date
Sep 9, 2025
Primary completion
Aug 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 22, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion